18550914. METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS simplified abstract (The General Hospital Corporation)
Contents
- 1 METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 How does this combination therapy compare to existing treatments for gynecologic cancers?
- 1.11 What are the potential long-term effects of using an anti-MUC16×CD3 multispecific immunoglobulin-related composition in cancer treatment?
- 1.12 Original Abstract Submitted
METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS
Organization Name
The General Hospital Corporation
Inventor(s)
David Spriggs of Boston MA (US)
Oladapo Yeku of Boston MA (US)
METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18550914 titled 'METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS
Simplified Explanation
The present technology provides methods for treating gynecologic cancers using combination therapy with an anti-MUC16×CD3 multispecific (e.g., bispecific) immunoglobulin-related composition that specifically binds to the C-terminal 114 amino acid residues of mature MUC16 (e.g., MUC16) and T cells, and a VEGF inhibitor. Kits for use in practicing the methods are also provided.
- Treatment of gynecologic cancers with combination therapy
- Utilizing an anti-MUC16×CD3 multispecific immunoglobulin-related composition
- Specifically binding to the C-terminal 114 amino acid residues of mature MUC16 and T cells
- Including a VEGF inhibitor in the treatment regimen
- Kits available for implementing the treatment methods
Potential Applications
The technology can be applied in the treatment of various gynecologic cancers, potentially improving patient outcomes and survival rates.
Problems Solved
This technology addresses the challenge of effectively treating gynecologic cancers by utilizing a combination therapy approach that targets specific cancer cells and inhibits VEGF, a key factor in tumor growth and progression.
Benefits
- Enhanced efficacy in treating gynecologic cancers - Targeted therapy with reduced side effects - Potential for improved patient quality of life
Potential Commercial Applications
The technology could have commercial applications in the pharmaceutical industry for the development and marketing of novel cancer treatments.
Possible Prior Art
Prior art may include existing therapies for gynecologic cancers, such as chemotherapy, radiation therapy, and targeted therapies. However, the specific combination therapy described in this patent application may represent a novel approach to treatment.
Unanswered Questions
How does this combination therapy compare to existing treatments for gynecologic cancers?
The article does not provide a direct comparison between this combination therapy and other standard treatments for gynecologic cancers. Further research or clinical trials may be needed to evaluate the efficacy and safety of this approach in comparison to existing therapies.
The long-term effects of using this specific composition in cancer treatment are not discussed in the article. Additional studies may be necessary to assess the potential risks and benefits of incorporating this component into the treatment regimen for gynecologic cancers.
Original Abstract Submitted
The present technology provides methods for treating gynecologic cancers using combination therapy with an anti-MUC16×CD3 multispecific (e.g., bispecific) immunoglobulin-related composition that specifically binds to the C-terminal 114 amino acid residues of mature MUC16 (e.g., MUC16) and T cells, and a VEGF inhibitor. Kits for use in practicing the methods are also provided.
